Abeona Therapeutics (ABEO) Competitors $6.27 -0.12 (-1.88%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$6.36 +0.09 (+1.42%) As of 04:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ABEO vs. HROW, WVE, CDTX, CVAC, AUPH, PRAX, CALT, PAHC, SRPT, and DYNShould you be buying Abeona Therapeutics stock or one of its competitors? The main competitors of Abeona Therapeutics include Harrow (HROW), WAVE Life Sciences (WVE), Cidara Therapeutics (CDTX), CureVac (CVAC), Aurinia Pharmaceuticals (AUPH), Praxis Precision Medicines (PRAX), Calliditas Therapeutics AB (publ) (CALT), Phibro Animal Health (PAHC), Sarepta Therapeutics (SRPT), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical products" industry. Abeona Therapeutics vs. Its Competitors Harrow WAVE Life Sciences Cidara Therapeutics CureVac Aurinia Pharmaceuticals Praxis Precision Medicines Calliditas Therapeutics AB (publ) Phibro Animal Health Sarepta Therapeutics Dyne Therapeutics Harrow (NASDAQ:HROW) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends. Which has better earnings and valuation, HROW or ABEO? Harrow has higher revenue and earnings than Abeona Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHarrow$199.61M6.10-$17.48M-$0.56-59.30Abeona Therapeutics$3.50M91.65-$63.73M-$1.27-4.94 Is HROW or ABEO more profitable? Abeona Therapeutics has a net margin of 0.00% compared to Harrow's net margin of -10.19%. Harrow's return on equity of -25.01% beat Abeona Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Harrow-10.19% -25.01% -4.27% Abeona Therapeutics N/A -118.82%-52.48% Do analysts recommend HROW or ABEO? Harrow currently has a consensus price target of $63.83, indicating a potential upside of 92.21%. Abeona Therapeutics has a consensus price target of $19.25, indicating a potential upside of 207.02%. Given Abeona Therapeutics' higher possible upside, analysts plainly believe Abeona Therapeutics is more favorable than Harrow.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Harrow 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Abeona Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in HROW or ABEO? 72.8% of Harrow shares are owned by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are owned by institutional investors. 15.2% of Harrow shares are owned by insiders. Comparatively, 6.9% of Abeona Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk & volatility, HROW or ABEO? Harrow has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Does the media refer more to HROW or ABEO? In the previous week, Harrow had 3 more articles in the media than Abeona Therapeutics. MarketBeat recorded 8 mentions for Harrow and 5 mentions for Abeona Therapeutics. Harrow's average media sentiment score of 0.17 beat Abeona Therapeutics' score of 0.15 indicating that Harrow is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Abeona Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryHarrow beats Abeona Therapeutics on 9 of the 15 factors compared between the two stocks. Get Abeona Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABEO vs. The Competition Export to ExcelMetricAbeona TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$326.89M$2.98B$5.48B$9.57BDividend YieldN/A2.46%3.99%4.17%P/E Ratio-4.9417.9729.8525.14Price / Sales91.65262.52422.3397.16Price / CashN/A41.8335.9458.58Price / Book6.217.238.125.59Net Income-$63.73M-$54.43M$3.26B$265.48M7 Day Performance-3.39%0.22%0.68%1.22%1 Month Performance7.36%5.59%2.46%0.39%1 Year Performance40.27%9.98%27.99%23.47% Abeona Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABEOAbeona Therapeutics3.8846 of 5 stars$6.27-1.9%$19.25+207.0%+41.9%$326.89M$3.50M-4.9490Upcoming EarningsHROWHarrow2.3192 of 5 stars$34.86-3.7%$63.83+83.1%+51.1%$1.33B$199.61M0.00180WVEWAVE Life Sciences4.7003 of 5 stars$8.18-2.6%$20.43+149.7%+36.0%$1.31B$108.30M-9.74240CDTXCidara Therapeutics3.3764 of 5 stars$62.68+1.3%$57.29-8.6%+456.1%$1.25B$1.27M-2.1390Earnings ReportCVACCureVac4.466 of 5 stars$5.42-0.7%$6.83+26.1%+64.5%$1.22B$579.18M5.89880News CoverageUpcoming EarningsAUPHAurinia Pharmaceuticals2.1471 of 5 stars$8.89-0.4%$11.50+29.4%+114.8%$1.21B$235.13M31.75300Insider TradePRAXPraxis Precision Medicines1.6617 of 5 stars$55.65-6.0%$94.11+69.1%-9.1%$1.21B$8.55M-5.19110Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180PAHCPhibro Animal Health4.0912 of 5 stars$28.92-0.9%$24.40-15.6%+60.8%$1.18B$1.02B37.081,940Positive NewsSRPTSarepta Therapeutics4.6213 of 5 stars$13.86+16.2%$51.42+271.0%-87.2%$1.17B$1.90B-5.151,372Trending NewsEarnings ReportAnalyst ForecastGap UpDYNDyne Therapeutics3.3786 of 5 stars$9.31-6.4%$40.63+336.4%-73.5%$1.13BN/A0.00100Upcoming EarningsAnalyst Forecast Related Companies and Tools Related Companies Harrow Alternatives WAVE Life Sciences Alternatives Cidara Therapeutics Alternatives CureVac Alternatives Aurinia Pharmaceuticals Alternatives Praxis Precision Medicines Alternatives Calliditas Therapeutics AB (publ) Alternatives Phibro Animal Health Alternatives Sarepta Therapeutics Alternatives Dyne Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABEO) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abeona Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Abeona Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
